Printer Friendly

BIOGEN ANNOUNCES THAT U.K. HIGH COURT UPHOLDS ITS PATENT ON HEPATITIS B ANTIGENS

 CAMBRIDGE, Mass., Nov. 4 /PRNewswire/ -- Biogen, Inc. (NASDAQ: BGEN) today announced that the High Court in London has ruled that Medeva plc's hepatitis B vaccine infringes Biogen's patent for hepatitis B antigens.
 Jim Vincent, Biogen's chairman and chief executive officer, said, "Hepatitis B vaccines based on Biogen's patented technology are sold worldwide and are among the most important products to have emerged from the biotechnology revolution. We are delighted by today's decision, which reaffirms the strength of our hepatitis B antigen patent position. The decision is an important step in preventing Medeva from marketing a vaccine that infringes on Biogen's patents." Biogen derives royalty revenues for hepatitis B vaccines from its licensees, SmithKline Beecham and Merck.
 Biogen, Inc, headquartered in Cambridge, Mass., is a biopharmaceutical company principally engaged in developing and manufacturing drugs for human healthcare through genetic engineering. The company's revenues are generated form the world wide sales by licensees of five products, including alpha interferon and hepatitis B vaccines and diagnostic products. Biogen is focused primarily on developing and testing products for the treatment of cardiovascular disease, inflammatory diseases, AIDS, and other cancers and viruses.
 -0- 11/4/93
 /CONTACT: Kathryn R. Bloom, director of communications, 617-252-9851, (media), or Amy S. Hedison, director of investor relations, 617-252-9873, (investment community), both of Biogen/
 (BGEN)


CO: Biogen, Inc. ST: Massachusetts IN: MTC SU:

JL-DJ -- NE009 -- 0608 11/04/93 10:24 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 4, 1993
Words:232
Previous Article:FILENE'S BASEMENT REPORTS OCTOBER SALES
Next Article:NESTLE AND NUTRASWEET ANNOUNCE JOINT VENTURE; LAUNCH OF NEW TABLETOP PRODUCT LINE IN MEXICO
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters